



Dr_WagdyMohamed-d_H


Sample Name Dr_WagdyMohamed-d_H
Date collected 2017-01-22

Pulse sequence CARBON
Solvent dmsd


Temperature 25
Spectrometer nmr400-mercury400

Study owner vnmr1
Operator vnmr1











NL: 6.03E5
ESI75854 #13-27 RT: 0.15-0.31 AV: 8 NL:
5.30E+006
T: FTMS {1,1} + p ESI Full lock ms
[80.00-1600.00]





Measured
Spectrum











Dr_WagdyMohamed-h_H



Sample Name Dr_WagdyMohamed-h_H
Date collected 2017-02-19

Pulse sequence PROTON
Solvent dms

Temperature 25
Spectrometer nmr400-mercury400

Study owner vnmr1
Operator vnmr1









Sample Name Dr_WagdyMohamed-h_H
Date collected 2017-02-19

Pulse sequence CARBON
Solvent dms

Temperature 25
Spectrometer nmr400-mercury400

Study owner vnmr1
Operator vnmr1







NL: 8.49E5
ESI75853 #13-27 RT: 0.14-0.31 AV: 8 NL:
1.20E+007
T: FTMS {1,1} + p ESI Full lock ms
[80.00-1600.00]

Measured
Spectrum

Sample Name **Dr_WagdyMohamed-i_H-D2O** Pulse sequence **PROTON**
Date collected **2017-01-24** Solvent **dmsol**

Temperature **25**
Spectrometer **nmr400-mercury400**

Study owner **vnmr1**
Operator **vnmr1**





Dr_WagdyMohamed-i_H

Sample Name Dr_WagdyMohamed-i_H
Date collected 2017-01-23

Pulse sequence PROTON
Solvent dms

Temperature 25
Spectrometer nmr400-mercury400

Study owner vnmr1
Operator vnmr1







WagdyMohamed-j_H




Sample Name **Dr_WagdyMohamed-j_H**
Date collected **2017-01-23**



Pulse sequence **PROTON**
Solvent **dms**

Temperature **25**
Spectrometer **nmr400-mercury400**

Study owner **vnmr1**
Operator **vnmr1**









Dr_WagdyMohamed-k_H

Sample Name Dr_WagdyMohamed-k_H
Date collected 2017-02-19

Pulse sequence CARBON
Solvent dmsd

Temperature 25
Spectrometer nmr400-mercury400

Study owner vnmr1
Operator vnmr1





Sample Name Dr_WagdyMohamed-n_H
Date collected 2017-02-18

Pulse sequence PROTON
Solvent dmsd

Temperature 25
Spectrometer nmr400-mercury400

Study owner vnmr1
Operator vnmr1

Dr_WagdyMohamed-n_H





Dr_WagdyMohamed-n_H



Sample Name Dr_WagdyMohamed-n_H
Date collected 2017-02-18

Pulse sequence CARBON
Solvent dmsd

Temperature 25
Spectrometer nmr400-mercury400

Study owner vnmr1
Operator vnmr1

Dr_WagdyMohamed-n_H



Developmental Therapeutics Program

NSC: D-808740 / 1

Conc: 1.00E-5 Molar

Test Date: Oct 01, 2018

One Dose Mean Graph

5a


Experiment ID: 1810OS18

Report Date: Oct 28, 2018

Panel/Cell Line

Growth Percent

Mean Growth Percent - Growth Percent



150 100 50 0 -50 -100 -150

Developmental Therapeutics Program

NSC: D-808667 / 1

Conc: 1.00E-5 Molar

Test Date: Oct 01, 2018

One Dose Mean Graph

5b

Experiment ID: 1810OS18

Report Date: Oct 28, 2018

Panel/Cell Line

Growth Percent

Mean Growth Percent - Growth Percent

Leukemia

CCRF-CEM	104.89
HL-60(TB)	84.77
K-562	88.21
MOLT-4	92.28
RPMI-8226	92.16
SR	96.62

Non-Small Cell Lung Cancer

A549/ATCC	104.81
EKVX	99.61
HOP-62	95.67
HOP-92	87.01
NCI-H226	102.97
NCI-H23	106.78
NCI-H322M	102.44
NCI-H460	104.96
NCI-H522	80.34

Colon Cancer

COLO 205	110.30
HCC-2998	103.39
HCT-116	97.28
HCT-15	110.25
HT29	102.93
KM12	102.43
SW-620	103.87

CNS Cancer

SF-268	94.50
SF-295	104.17
SF-539	95.74
SNB-19	95.64
SNB-75	81.43
U251	97.14

Melanoma

LOX IMVI	96.20
MALME-3M	93.20
M14	102.47
MDA-MB-435	97.73
SK-MEL-2	95.34
SK-MEL-28	110.07
SK-MEL-5	90.18
UACC-257	101.79
UACC-62	74.95

Ovarian Cancer

IGROV1	74.89
OVCAR-3	112.96
OVCAR-4	97.74
OVCAR-5	107.74
OVCAR-8	100.65
NCI/ADR-RES	98.23
SK-OV-3	96.27

Renal Cancer

786-0	103.70
A498	95.05
ACHN	98.18
CAKI-1	88.64
RXF 393	96.04
SN12C	94.69
TK-10	104.34
UO-31	75.76

Prostate Cancer

PC-3	89.40
DU-145	108.64

Breast Cancer

MCF7	90.11
MDA-MB-231/ATCC	105.22
HS 578T	89.55
BT-549	89.13
T-47D	87.53
MDA-MB-468	110.20

Mean	96.99
Delta	22.10
Range	38.07

150 100 50 0 -50 -100 -150

Developmental Therapeutics Program

NSC: D-808669 / 1

Conc: 1.00E-5 Molar

Test Date: Oct 01, 2018

One Dose Mean Graph

5c


Experiment ID: 1810OS18

Report Date: Oct 28, 2018

Panel/Cell Line

Growth Percent

Mean Growth Percent - Growth Percent



150 100 50 0 -50 -100 -150

Developmental Therapeutics Program

NSC: D-808671 / 1

Conc: 1.00E-5 Molar

Test Date: Oct 01, 2018

One Dose Mean Graph

5d

Experiment ID: 1810OS18

Report Date: Oct 28, 2018

Panel/Cell Line

Growth Percent

Mean Growth Percent - Growth Percent

Leukemia

CCRF-CEM	102.17
HL-60(TB)	88.51
K-562	94.64
MOLT-4	81.26
RPMI-8226	107.46
SR	85.23

Non-Small Cell Lung Cancer

A549/ATCC	95.42
EKVX	108.09
HOP-62	114.34
HOP-92	109.36
NCI-H226	105.47
NCI-H23	94.93
NCI-H322M	108.41
NCI-H460	108.03
NCI-H522	89.92

Colon Cancer

COLO 205	117.47
HCC-2998	100.29
HCT-116	99.33
HCT-15	90.64
HT29	103.17
KM12	102.56
SW-620	113.05

CNS Cancer

SF-268	105.63
SF-295	105.97
SF-539	101.82
SNB-19	103.38
SNB-75	92.63
U251	98.99

Melanoma

LOX IMVI	98.96
MALME-3M	99.04
M14	110.24
MDA-MB-435	92.89
SK-MEL-2	102.16
SK-MEL-28	118.17
SK-MEL-5	96.95
UACC-257	104.89
UACC-62	99.44

Ovarian Cancer

IGROV1	99.18
OVCAR-3	111.25
OVCAR-4	90.61
OVCAR-5	103.37
OVCAR-8	98.30
NCI/ADR-RES	99.33
SK-OV-3	100.00

Renal Cancer

786-0	100.22
A498	103.12
ACHN	108.14
CAKI-1	93.94
RXF 393	116.41
SN12C	94.76
TK-10	104.36
UO-31	87.03

Prostate Cancer


PC-3	96.50
DU-145	104.56

Breast Cancer

MCF7	103.74
MDA-MB-231/ATCC	104.11
HS 578T	117.17
BT-549	105.04
T-47D	101.03
MDA-MB-468	110.54

Mean	101.73
Delta	20.47
Range	36.91

150 100 50 0 -50 -100 -150



Developmental Therapeutics Program

NSC: D-808743 / 1

Conc: 1.00E-5 Molar

Test Date: Oct 01, 2018

One Dose Mean Graph

5e


Experiment ID: 1810OS18

Report Date: Oct 28, 2018

Panel/Cell Line

Growth Percent

Mean Growth Percent - Growth Percent



150 100 50 0 -50 -100 -150

Developmental Therapeutics Program

NSC: D-808745 / 1

Conc: 1.00E-5 Molar

Test Date: Oct 01, 2018

One Dose Mean Graph

5f


Experiment ID: 1810OS18

Report Date: Oct 28, 2018

Panel/Cell Line

Growth Percent

Mean Growth Percent - Growth Percent



150 100 50 0 -50 -100 -150

Developmental Therapeutics Program

NSC: D-808744 / 1

Conc: 1.00E-5 Molar

Test Date: Oct 01, 2018

One Dose Mean Graph

5g


Experiment ID: 1810OS18

Report Date: Oct 28, 2018

Panel/Cell Line

Growth Percent

Mean Growth Percent - Growth Percent



150 100 50 0 -50 -100 -150

Developmental Therapeutics Program

NSC: D-808742 / 1

Conc: 1.00E-5 Molar

Test Date: Oct 01, 2018

One Dose Mean Graph

5h


Experiment ID: 1810OS18

Report Date: Oct 28, 2018

Panel/Cell Line

Growth Percent

Mean Growth Percent - Growth Percent



150 100 50 0 -50 -100 -150